Dr. Moses is Senior Vice President and Global Chief Medical Officer at Novo Nordisk A/S. In this role he has responsibilities across the full spectrum of Novo Nordisk’s diabetes focus from drug discovery through drug development, brand messaging, and the implications of diabetes for the company, patients, healthcare professionals and healthcare systems.
Since joining Novo Nordisk in 2004, Dr. Moses has held positions of increasing responsibility in Clinical Development and Medical Affairs. His research interests have been in endocrine cell growth in response to peptide growth factors, the pathophysiology of severe insulin resistance and novel treatments for diabetes mellitus.
He has also served as Professor of Medicine at the Harvard Medical School and Chief Medical Officer of the Joslin Diabetes Center.
Dr. Moses was educated at Duke University (BS) and Washington University School of Medicine (MD). He received medical training at Barnes Hospital, the National Institutes of Health, and Tufts-New England Medical Center. He is board certified in Internal Medicine and Endocrinology and Metabolism.